Illumina® DRAGEN™ Secondary Analysis
Last updated
Was this helpful?
Last updated
Was this helpful?
Illumina DRAGEN (Dynamic Read Analysis for GENomics) secondary analysis was developed to address important challenges associated with analyzing NGS (Next Generation Sequencing) data for a range of applications, including genome, exome, transcriptome, and methylome studies. DRAGEN secondary analysis processes NGS data and enables tertiary analysis to drive insights. The available tools make up a highly accurate, comprehensive, and efficient solution that enables labs of all sizes and disciplines to do more with their genomic data.
Product highlights
Accurate results:
Pangenome reference genome and machine learning drive unprecedented accuracy
99.89% accuracy score with the Precision FDA Truth Challenge V2 benchmark data (2,3)
Comprehensive platform:
Analyze NGS data from whole genomes, exomes, methylomes, and transcriptomes
Available on platform of choice and scalable based on needs
Efficient analysis:
Process a 34x genome in ~ 30 minutes, with all supported callers with DRAGEN server v4 (1)
Reduce FASTQ file sizes up to 5x with DRAGEN ORA Compression
References:
Illumina data on file, 2022.
Illumina DRAGEN Secondary Analysis is the first single platform to achieve 99.89% accuracy based on PrecisionFDA v2 Truth Challenge Benchmark Data. Details here DRAGEN sets new standard for data accuracy in PrecisionFDA benchmark data. Accessed March 22, 2023
PrecisionFDA Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions. precision.fda.gov/challenges/10. Accessed November 3, 2020.
